organization

FUNDACION PRIVADA INSTITUTO DEINVESTIGACION ONCOLOGICA DE VALL-HE

FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO)
  • Country: Spain
20 projects, page 1 of 4
  • project . 2022 - 2024
    Funder: EC Project Code: 101025901
    Overall Budget: 172,932 EURFunder Contribution: 172,932 EUR
    Open Access mandate for Publications and Research Data
    Partners: FUNDACION PRIVADA INSTITUTO DEINVESTIGACION ONCOLOGICA DE VALL-HE

    Metastatic prostate cancer (mPC) is a lethal disease. Androgen deprivation therapy is the mainstay of patient care. In addition, DNA repair defects is a novel therapeutic target in mPC. However, resistances invariably arise, triggered most of the times by tumor genomic ...

  • project . 2019 - 2021
    Funder: EC Project Code: 837900
    Overall Budget: 172,932 EURFunder Contribution: 172,932 EUR
    Open Access mandate for Publications and Research Data
    Partners: FUNDACION PRIVADA INSTITUTO DEINVESTIGACION ONCOLOGICA DE VALL-HE

    Prostate cancer is the 2nd most common cancer in the western world. The advanced stage, metastatic castration-resistant prostate cancer (mCRPC), is a lethal disease. Understanding inter-patient genomic heterogeneity renders the opportunity to advance towards personalise...

  • project . 2015 - 2016
    Funder: EC Project Code: 665671
    Overall Budget: 150,000 EURFunder Contribution: 150,000 EUR
    Open Access mandate for Publications
    Partners: FUNDACION PRIVADA INSTITUTO DEINVESTIGACION ONCOLOGICA DE VALL-HE

    Global cancer market is growing at a CAGR of 6.9% with an estimated value of $81bn in 2016. Although the huge R&D investment observed in the past years in the development of new treatments, there is still lack on an effective treatment in many tumour types. In particula...

  • project . 2016 - 2017
    Funder: EC Project Code: 713551
    Overall Budget: 147,750 EURFunder Contribution: 147,750 EUR
    Open Access mandate for Publications
    Partners: FUNDACION PRIVADA INSTITUTO DEINVESTIGACION ONCOLOGICA DE VALL-HE

    Despite ever-increasing investments in the development of new treatments, many cancers remain incurable. One reason is that most current therapies target redundant functions around which tumour cells can build resistance. We focus instead on a unique and essential cellu...

  • project . 2018 - 2019
    Funder: EC Project Code: 813132
    Overall Budget: 148,875 EURFunder Contribution: 148,875 EUR
    Open Access mandate for Publications
    Partners: FUNDACION PRIVADA INSTITUTO DEINVESTIGACION ONCOLOGICA DE VALL-HE

    Current cancer therapies target redundant cellular functions often compensated for by cancer cells, resulting in resistance to treatment. Here we propose an innovative approach to inhibit Myc, a non-redundant and “most-wanted” therapeutic target for human cancer. Target...

20 projects, page 1 of 4
Any information missing or wrong?Report an Issue